Investment Thesis
Pyxis Oncology faces critical financial distress with a cash burn rate of $63.5M annually against only $15.4M cash reserves, implying ~3 months of runway. The company generates minimal revenue ($13.9M, declining YoY) while operating at massive losses (-609% operating margin), indicating pre-commercial status with no path to profitability visible in current financials.
Strengths
- Zero debt maintains balance sheet flexibility
- Positive stockholders equity of $53.4M provides cushion
- Short-term liquidity ratios healthy (3.41x current ratio)
Risks
- Critical cash runway of ~3 months at current burn rate threatens company viability
- Revenue declining 14.2% YoY with minimal absolute scale ($13.9M)
- Operating losses of $84.4M annually indicate unsustainable business model
- Imminent need for dilutive capital raise or major operational restructuring
- No evidence of clinical success, regulatory approvals, or near-term revenue inflection
Key Metrics to Watch
- Cash burn rate and cash runway remaining
- Clinical trial progress and pipeline advancement
- Subsequent financing activities and dilution impact
- Quarter-over-quarter revenue trends and customer acquisition
Financial Metrics
Revenue
13.9M
Net Income
-79.6M
EPS (Diluted)
$-1.28
Free Cash Flow
-63.5M
Total Assets
91.5M
Cash
15.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-609.2%
Net Margin
-574.5%
ROE
-149.1%
ROA
-87.0%
FCF Margin
-458.3%
Balance Sheet & Liquidity
Current Ratio
3.41x
Quick Ratio
3.41x
Debt/Equity
0.00x
Debt/Assets
41.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-14T19:39:22.208673 |
Data as of: 2025-12-31 |
Powered by Claude AI